Becton, Dickinson and Company (BD) has reported $4.76bn revenue in the fourth quarter (Q4) of the fiscal year 2022, representing a 1.8% decline compared to $4.84bn in the same quarter of the previous year.
The revenue performance was driven by 4.2% growth in base revenue, reaching $4.72bn from $4.5bn reported the prior year, and 8.6% on a currency-neutral basis.
During the quarter, the company’s GAAP stood at $0.92, while adjusted diluted EPS was at $2.75.
The company’s BD Medical segment reported $2.3bn in revenues, representing a 5.8% increase from $2.2bn in the same quarter of the previous year.
In the BD Life Sciences segment, $1.28bn revenue was generated, a 15.9% decline from the year-ago quarter.
The BD Interventional segment generated $1.09bn revenue, showing a 2.4% increase from the year-ago quarter.
For the full year of fiscal 2022, BD generated $18.9bn revenue, a 1.4% decrease and 0.9% increase on a currency-neutral basis.
Its revenue performance was driven by 6.9% growth and 9.4% on a currency-neutral basis.
GAAP for the complete fiscal year 2022 stood at $5.38 and the adjusted diluted EPS at $11.35.
BD chairman, CEO and president Tom Polen said: “Fiscal 2022 was another outstanding year with impactful results that confirm the effectiveness of our BD 2025 strategy.
“We delivered reliable, consistent performance that reflects our team’s unwavering commitment to our purpose and the execution of our growth plan – while navigating the challenging macro environment all companies are facing.
“Looking forward, our strong performance and momentum increases our confidence to continue to create substantial, sustained value for all stakeholders.”
Recently, the company launched the BD Research Cloud software solution in the US as well as the BD Effivax next-generation glass prefillable syringe.